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Abstract 
The blood sugar lowering effect of the aqueous extract of Sarcocephalus latifolius S. M. 
(Rubiaceae) and Daniella oliveri Rolfe (Caesalpiniaceae) roots (250mg/kg) was investigated on 
normoglycaemic and alloxan induced diabetic rats. In addition, hexokinase, glucokinase and 
phosphofructokinase activities as well as hepatic glycogen content were assessed. The extract’s 
potency was compared with a standard drug, glibenclamide. The test dose of the extract caused a 
significant (p<0.05) lowering of blood sugar level in alloxan diabetic rats within six hours; from 
261.00±3.02 to 65.00±5.40 and from 302.75±79.62 to 119.00±20.30 after three weeks. The same 
dose did not show blood sugar lowering effect in normoglycaemic rats. Diabetic rats showed 
significant (p<0.05) decrease in the activities of hepatic hexokinase, glucokinase, 
phosphofructokinase and hepatic glycogen content. The extract significantly (p<0.05) restored 
both hepatic glycogen content and the activities of hexokinase, glucokinase and 
phosphofructokinase. The oral LD50 of the extract in mice was greater than 5000 mg/kg. 
Phytochemical analysis of the extract revealed the presence of high levels of flavonoids, 
alkaloids, saponins, glycosides, steroids and terpenoids and moderate levels of tannins. The 
results indicate that the decoction of the roots of S. latifolius and D. oliveri has 
antihyperglycaemic effect. The probable mechanism of action of the extract is discussed and we 
suggest that the combination of the root extracts of S. latifolius and D. oliveri is a good option for 
alternative medicine in the management of diabetes mellitus. 
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In Nigeria, herbal therapies occupy a very 
special position in health delivery, especially 
among the rural populace. Easy accessibility 
and low cost of treatment enhance patronage.  
 
Diabetes mellitus is the commonest non-
communicable endocrine disease and is 
considered one of the leading causes of death 
all over the world; affecting over 100 million 
people worldwide1. Many traditional plant 
treatments for diabetes mellitus are used 
throughout the world, and some of these plants 
have been scrutinized while a good number of 




A decoction of the roots of Sarcocephalus 
latifolius (Rubiaceae) and Daniella oliveri 
(Caesalpiniaceae) is used in parts of the south 
eastern Nigerian folk medicine as herbal 
remedy for hyperglycaemia. Although, the 
antihyperglycaemic potential of the leaves3 of 
S. latifolius has been demonstrated, there is no 
scientific report on the blood sugar lowering 
activity of the roots of these plants in 
combination. A preliminary study in our 
laboratory showed the reduction of blood 
glucose in diabetic rats treated with root 
extract of S. latifolius4.  
 
This study was initiated with the primary aim 
of investigating the effect of aqueous extract 
of a combination of S. latifolius and D. Oliveri 
roots on the fasting blood glucose level. In 
addition, the effect of the extract on the 
activities of key glucose metabolic enzymes: 
hexokinase, glucokinase, phosphofructokinase 
and glycogen concentration in the livers of 
non-diabetic and alloxan-induced diabetic rats 
were also evaluated in the bid to understand 
the probable mechanism of 
antihyperglycaemic action of the extract.  
 
MATERIALS AND METHODS  
 
Materials  
Fresh roots of S. latifolius and D. oliveri were 
collected in November, 2006 from the plants 
in Nsukka, Enugu State, Nigeria. The plants 
were identified and authenticated by Mr. A. O. 
Ozioko of the International Centre for 
Ethnomedicine and Drug Development, 
Nsukka where the Voucher Specimens 
(InterCEDD 76AO and 158AO) respectively 
were deposited.  
Preparation of the Plant Extract  
The fresh roots of S. latifolius and D. oliveri 
were separately cleaned, chopped into pieces 
and shade-dried to a constant weight. 250 g 
each of the S. latifolius and D. oliveri root 
chips were collectively subjected to exhaustive 
extraction in 4 volumes (w/v) of distilled water 
by decoction. The extract was filtered with 
cheese cloth. The filtrate was dried at 40OC 
yielding about 38.49 g of a dark brown residue 
of Sarcocephalus/Daniella Aqueous (SDA). 
The extract was refrigerated and dissolved in 
distilled water before use. The extract was 
administered at a dose of 250 mg/kg body 
weight. This dosage was determined from a 
preliminary dose response study which 
showed that the 250 mg/kg body weight had 
the greatest hypoglycaemic effect.  
 
Animals  
Adult Sprague-Dawley (SD) rats weighing 300 
g and albino mice (15 – 35 g) of either sex 
were obtained from the Laboratory Animal 
Facilities of the Faculties of Veterinary 
Medicine and Biological Sciences, University 
of Nigeria, Nsukka. The animals were 
administered for about 7 days under standard 
environmental conditions with a 12 hour 
light/12 hour dark cycle and maintained on a 
regular feed (vital feed) and water ad 
libitum.The Institution’s Animal Ethics 
Committee of the Faculty  of Veterinary 
Medicine approved the study.  
 
Preliminary Phytochemical Screening  
Preliminary phytochemical tests were carried 
out on the extract using standard reagents and 
procedures5,6. In general, tests for the presence 
of phytochemical compounds involve the 
addition of appropriate chemical reagent(s) to 
the extract in separate test tubes. The mixture 
was then shaken and/or heated as the case may 
be. The presence or absence of saponins, 
flavonoids, tannins, alkaloids, etc was 
observed.  
 
Acute Toxicity Test  
The oral median lethal dose (LD50) of the 
extract was determined in albino mice using 
the method of Lorke7. This study was 
conducted in two stages; an initial dose-range 
determination stage involving 9 animals (3 
groups of 3 animals each) treated p.o. with 10, 
100 and 1000 mg/kg of the SDA extract. The 
animals were observed for number of deaths 
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and behavioural changes for seventy two 
hours. Based on the percentage survival rates, 
the second stage was carried out in which three 
groups of mice were treated with 1500, 2900 
and 5000 mg/kg of the extract and observed as 
in the first stage. The LD50 was then 
calculated as the geometric mean of the 
highest non-lethal and the lowest lethal doses.  
 
Induction of Experimental Diabetes 
Mellitus  
Rats fasted for 16 hours, but with free access 
to water were made diabetic by an intravenous 
injection of alloxan monohydrate (Sigma-
Aldrich, U.S.A.) (65 mg/kg) given in the tail 
vein. The alloxan was dissolved in sterile 
normal saline just prior to injection; the 
injection volume was 1 ml/kg. Since alloxan is 
capable of producing fatal hypoglycaemia as a 
result of massive pancreatic insulin release, the 
rats were treated with 20% glucose solution 
after 3 hours. The animals were further kept 
for the next 12 hours with 5% glucose solution 
bottles in their cages to prevent 
hypoglycaemia8. After 12 hours of alloxan 
injection, surviving rats with fasting blood 
glucose levels ≥ 200 mg/dl were included in 
the study. Animals had free access to food and 
water after alloxan injection.  
 
Repeated Administration of SDA to 
Alloxan-Diabetic Rats  
Before treating the animals as shown in Table 
1, the animals were fasted for 16 hours and 
their fasting blood glucose levels were 
determined using One Touch Ultra Blood 
glucose monitor (Lifescan, a Johnson and 
Johnson Company, U.K.). The treatment was 
administered orally by intubation twice daily 
to the various groups for 21 consecutive days. 
At the end of the treatment days, the animals 
fasting blood glucose levels were determined 
again. The animals were then euthanized using 
and their livers were surgically removed 
immediately, washed with ice cold KCl 
(1.15%) and refrigerated. The liver tissues 
were used for the biochemical assay of 
hexikinase, glucokinase, phosphofructokinase 
and hepatic glycogen within one week of 
collection.  
 
Hepatic Hexokinase (EC. 2.7.1.2) Activity  
Liver tissues (0.5 g) were homogenized with 
ten times their weight in volume of the 
homogenizing buffer (50 nM Tris/HCl, pH 
7.5, 2 mM mgCl2, 1mM EDTA and 30 mM 
DTT). The homogenates were centrifuged at 
20,000 g for 15 mins at 4OC and the 
supernatants used for the enzyme assay. The 
enzyme activity, using a coupled assay with 
gluco-6-phosphate dehydrogenase, was 
monitored at 37
O
C by following the 
appearance of NADPH at 340 nm for 3 
minutes at 30 seconds interval according to the 
method of Lapeir and Rodnick
9





Hepatic Glucokinase (EC 2.7.1.3) Activity  
Liver tissues (0.5g) were homogenized in nine 
volumes of the homogenizing buffer (100 mM 
KCl, 10 mM DTT, 50 mM Tris/HCl and 1 mM 
EDTA at pH 7.4). The hepatic glucokinase 
activity was determined according to the 
method of Newgard et al.
11
, which was 
modified and reported by Ugochukwu and 
Babady10. The production of glucose-6-
phosphate by glucokinase in the presence of 
ATP was linked to the reduction of NAD to 
NADH by glucose-6-phosphate 
dehydrogenase from Leuconostoc 
mesenteroides.  
 
Hepatic Phosphofructokinase (EC 2.7.1.11) 
Activity  
Liver tissues (0.5 g) were homogenized with 
ten times their weight in volume of (50 mM 
Tris/HCl, pH 8.5, 5 mM MgSO4.7H2O, 1 mM 
EDTA and 10 mM DTT). The homogenates 
were centrifuged at 20,000 g for 15 minutes at 
4OC. Supernatants (50 µl) were used for the 
enzyme assay. The supernatants and the other 
components of the reaction mixture12 in a final 
volume of 1 ml were incubated at 37
O
C and 
the change in absorbance (appearance of 
NADH) was followed at 340 nm for 3 minutes 
at 30 seconds interval.  
 
    Table 1: Experimental Design 
S/No Group Number of Rats Treatment 
1 Normal Control (NC) 4 Distilled water (5ml/kg) 
2 Diabetic Control (DC) 4 250 mg/kg SDA 
3 Diabetic SDA (DSDA) 4 5 mg/kg 
4 Glibenclamide 4 Distilled water (5 ml/kg) 
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Hepatic Glycogen Content  
Glycogen content was measured as described 
by Ong and Khoo13. Liver tissues (0.5 g) were 
homogenized in 10 ml volumes (w:v) of ice-
cold 30% KOH and boiled at 100
0
C for 30 
minutes. Glycogen was precipitate with 
ethanol, pellet, washed and resolubilised in 
distilled water. Glycogen content was 
determined by treatment with anthrone reagent 
and measured at 625 nm.  
 
Protein Determination  
Protein content of the liver tissues was 
determined by the Biuret method as described 
by Gornal et al.14 using Bovine Serum 
Albumin (BSA) as standard.  
 
Statistical Analysis  
The results are presented as mean ± SEM for 4 
– 6 rats in each group. The results were 
analysed for statistical significance by One-
Way ANOVA test and was further subject to 
Fischer LSD post Hoc test using the SPSS 
Genstat Release (Windows 98) Software 
Package Version 11. Differences between 




Phytochemical Test  
Phytochemical investigation revealed the 
presence of biological active constituents in 
the extract. The extract gave positive reactions 
for flavonoids, alkaloids, saponins, tannins, 
carbohydrates, reducing sugars, glycosides, 
steroids and terpenoids as shown in Table 2.  
 
Acute Toxicity Test  
The safety of the extract is evidenced by the 
high LD50 value of the extract (>5g/kg). In 
addition, there were no significant 
modification in the general behaviour of the 
animals nor were there death after 72 hours at 
the highest administered dose (5g/kg) of the 
extract.  
 
Fasting Blood Glucose Level  
Prior to treatment, the fasting blood glucose 
levels of the alloxan-induced diabetic rats were 
significantly (p<0.05) higher than the fasting 
blood glucose level (FBGL) of the non-
diabetic control rats. Within seven days of 
treatment there was a significant increase 
(p<0.05) in the FBGL of the group of rats 
treated with the extract (Table 3). Continued 
daily administration of the extract for 21 days 
caused a significant reduction (p<0.05) in the 
blood glucose level when compared with the 
diabetic control group of rats. Similarly, 
repeated administration of glibenclamide 
(5mg/kg) for 21 days produced a significant 
reduction in the FBGL in alloxan-induced rats 
relative to the diabetic control group and the 
initial day values.  
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 Table 3: Fasting blood glucose level in alloxan diabetic rats 
Treatment Group                  Fasting Blood Glucose Level (mg/dl) 
Initial Seventh Day Final (21 Days) 
Normal Control 75.25±13.88 85.75±8.18 72.25±8.62 
Diabetic Control 228.5±32.89 256.25±15.50 285.50±13.03 
Diabetic-SDA 302.75±79.62 341.50±12.82* 119.00±20.34* 
Diabetic-Glib. 256.25±65.79 167.25±9.90 120.00±5.16* 
Diabetic-SDA (Diabetic treated with extract), Diabetic-Glib (Diabetic-treated with glibenclamide 
water), Diabetic control (Diabetic treated with distilled water). Values are expressed as mean ± 
SEM (n = 4). *P<0.05 indicates a significant difference compared with the initial value. 
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Hepatic Enzymes  
The activities of hepatic hexokinase (HK), 
glucokinase (GK) and Phosphofructokinase 
(PFK) in normal and diabetic rats treated 
repeatedly for 21 days with the extract, 
glibenclamide and distilled water were 
determined and the results shown in Figures 
1a, b and c. As compared to the normal control 
values, mean levels of the enzymes (HK, GK 
and PFK) activities decreased in the diabetic 
control. Treatment with the extract and 
glibenclamide led to a rise in the activities of 
these enzymes when compared with the 
diabetic control group of rats.  
Fig. 1c: Phosphofructokinase Activities in normal and diabetic 



























































































Hepatic Glycogen Content  
Glycogen content of the liver tissues was 
estimated after 21 days of repeated treatment 
with the extract (SDA), glibenclamide and 
distilled water in normal and diabetic rats as 
shown in Fig. 2. In diabetic control animals, 
hepatic glycogen content decreased 
significantly when compared with the non-
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diabetic controls. Treatment with the extract 
(SDA) and glibenclamide increased the 
hepatic glycogen content with SDA being 
significant at p<0.05 in comparison to the 




Available drug regimens for the management 
of diabetes mellitus have certain disadvantages 
15,16,
 and so there is need to develop new 
therapies that can improve hyperglycaemic 
management, but with reduced side effects.  
 
Our results indicate that the extract of the two 
plants S. latifolius and D. oliveri in 
combination has rich phytochemical 
constituents and one or more of these may be 
responsible for the hypoglycaemic activity. 
Studies carried out to access the safety of this 
extract using mice revealed a high margin of 
safety LD50 > 5 g/kg.  
 
Alloxan produces hyperglycaemia by selective 
cytotoxic effect on pancreatic ß-cells17,18, 
causing permanent destruction of ß-cells. The 
65 mg/kg dose of alloxan used in this study, 
caused moderate diabetes19. It has been 
reported that glibenclamide was not very 
effective when complete destruction of ß-cells 
has occurred and hence more effective in 




Daily administration of SDA (250 mg/kg) and 
glibenclamide (5 mg/kg) to the diabetic rats 
twice daily for 21 days resulted in a significant 
reduction (61% and 53% respectively) in 
fasting blood glucose levels. Repeated 
administration of this extract twice daily 
elicited an initial increase in the fasting blood 
glucose levels of the diabetic rats which 
subsequently decreased.  
 
This finding explains the assertion of 
tradomedical practitioners; that the 
combination therapy demonstrates initial rise 
in FBGL which goes down after sometimes 
and then stabilizes. In view of this, unlike the 
sulphonylureas or insulin, the onset of action 
of the extract is slow and so cannot be used for 
the management of emergency situations.  
 
The anti-hyperglycaemic activity of SDA 
exceeded that of glibenclamide and hence the 
inference that this extract may be more 
efficacious as more than one component may 
be responsible for the activity.  
 
Diabetes mellitus is known to be associated 
with a reduced capacity of the ß-cells of the 
pancreas to release sufficient insulin which 
induces the activity of glucose metabolizing 
enzymes
21
. Our results indicate that the 
activities of hexokinase, glucokinase and 
phosphofructokinase were significantly 
depressed in the untreated diabetic rats. These 
results are consistent with the reports of other 






Treatment of the diabetic rats with the extract 
(SDA) showed an increased hexokinase, 
glucokinase and phosphofructokinase 
activities. The mechanism(s) of action of SDA 
is not yet known exactly, but from its effect on 
these glycolytic enzymes, it seems to increase 
flux of glucose into the glycolytic pathway in 
an attempt to reduce high blood glucose 
concentration.  
 
Reduction in these enzyme activities in 
diabetic animals has been reported to give rise 
to a depletion of liver glycogen 27,28. Some 
studies have demonstrated that hepatic 
glycogen content in untreated diabetic rats was 
higher than in treated and untreated non-
diabetic rats
29,10
. In this study, the hepatic 
glycogen content was reduced significantly in 
diabetic controls as compared to the normal 
control animals. This is in agreement with 
earlier findings and was also supported by the 
findings of 30,19,31 who demonstrated that 
glycogen deposition from glucose is impaired 
in diabetic animals proportional to the severity 
of insulin deficiency32,33. Some workers have 




Treatment of the diabetic rats with SDA 
inhibited the said depletion in glycogen 
content and almost normalized it. This is 
possibly due to either the stimulation of insulin 
release from ß-cell
35
 or insulinomimetic 
activities of the extract giving rise to direct 
peripheral glucose uptake or a combination of 
the two.  
 
In conclusion, we suggest that the combination 
of the roots extracts of S. latifolius and D. 
oliveri is a good option for alternative 
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